no icon
no icon
amc icon

Nippon India Pharma Fund Direct Plan Growth Plan - Growth Option Growth

Equity | Sector Specific - Pharma

(NAV as of 12/04/2024)
469.54 (-1.15)

3Y Returns

17.74%

Min SIP

100

Min Lumpsum

5000

Expense Ratio

0.94%

Fund Size

6470 Cr

Inception Date

01-Jan-13

Fund Manager

Sailesh Raj Bhan

Exit Load

1% on or before 1M, Nil after 1M.

Wealthzi View

Market Risk / Risk Taken Compared to Benchmark

Fund Size

SIP Returns

Risk Adjusted Returns

Extra Returns Over Benchmark

Returns Consistency

Performance Against Inflation

Overall Fund Zi Tag

Asset Allocation

Equity

98.54%

Debt & Others

1.46%

Market Cap Allocation

Large Cap

39.07%

Mid Cap

37.52%

Small Cap

21.95%

Other Cap

1.46%

Sector Allocation

Pharmaceuticals

77.84%

Health Care

18.19%

Retailing

3.20%

Cash/Deposits/Margins/Treps/Repo/Swaps

0.77%

Top Ten Holdings

Sun Pharmaceutical Industries Ltd

13.50%

Lupin Ltd

8.31%

Cipla Ltd

6.08%

Apollo Hospitals Enterprises Ltd

5.98%

Dr. Reddy'S Laboratories Ltd

4.89%

Investment Objective

The Primary Investment Objective Of The Scheme Is To Generate Consistent Returns By Investing In Equity / Equity Related Or Fixed Income Securities Of Pharma And Other Associated Companies

Fund House Detail

AMC Name

Nippon Life India Asset Management Limited

Address

Reliance Centre, 7th Floor,South Wing, Off Western Express Highway, Santacruz (East)Mumbai - 400 055

BUILD WEALTH WITH CONFIDENCE

no iconno iconno iconno icon
no icon

BSE Member code: 58371

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.
get on play storeget on app store

Wealthzi Investment Advisers (A division of Lime Internet Private Limited)

[CIN: U74999DL2017PTC310507] [PAN: AADCL2103M] [GSTIN: 07AADCL2103M1ZP]

[SEBI Registered Name: Lime Internet Private Limited] [SEBI RIA Registration No: INA000018133] [BASL Member ID: 2014] [Type of Registration: Non-Individual] [Validity of Registration: Perpetual] [Registered Address: Flat No. 603, 6th Floor, Kanchenjunga Building, 18 Barakhamba Road, New Delhi - 110001] [Principal Officer: Jyoti Prakash Nayak, Email: [email protected]] [Compliance Officer: Harshit Singh, Email: [email protected]] [Grievance Officer: Sahad PV, Email: [email protected]]

[SEBI Regional Office Address: Securities and Exchange Board of India, NBCC Complex, Office Tower-1, 8th Floor, Plate B, East Kidwai Nagar, New Delhi - 110023, Ph: 011-69012998, Email: [email protected]]

Disclaimers:

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, membership of BASL and certification from National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

The information is only for consumption by the client and such material should not be redistributed.